secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0000950170-25-089218
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin licenses VAZKEPA to Recordati in Europe; launches restructuring targeting $70M annual savings
--------------------------------------------------------------------------------

- Upfront $25M and up to $150M in milestone payments; Recordati to commercialize VAZKEPA in 59 European countries.
- Global restructuring to cut operating costs by ~$70M annually; expects $30-37M in restructuring charges in Q2 2025.
- Company retains U.S. rights; nearly $300M cash on hand, no debt; accelerated path to positive cash flow.
- Agreement term 15 years, auto-renewal subject to commercialization in at least one country.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000095017025089218/0000950170-25-089218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000095017025089218/amrn-20250620.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-089218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer